WHO To Commence COVID-19 Vaccine Trials In Nigeria

The World Health Organization (WHO) has said that Nigeria has communicated enthusiasm to be a piece of the worldwide solidarity preliminary of the immunizations being created to handle COVID-19 pandemic and endeavors are in progress to begin the procedure in the nation. 

The Officer in control, WHO Nigeria and individual from the Presidential Task Force (PTF) on COVID-19, Dr. Fiona Braka, said this on Friday in Abuja, at the 24th joint national preparation of the advisory group. 

She additionally said that 89 antibodies are being grown universally, remembering seven for clinical assessment and a few therapeutics in clinical preliminaries to handle the COVID-19 pandemic. 

She said:-

“Nigeria has also expressed interest to be part of this solidarity trial and efforts are underway to start the process in Nigeria too.”

As per her, regarding the matter of antibodies and clinical preliminaries for Covid-19, innovative work is a significant part of the reaction and analysts around the globe are buckling down on quickening the advancement of immunizations and therapeutics for Covid-19. 

She said the WHO has propelled different working gatherings to quicken different parts of antibody advancement.

“Together with global health actors and partners, over the past week, WHO launched the Access to Covid-19 Tools ACT Accelerator, a global collaboration to accelerate development for equitable access to new Covid-19 diagnostics, therapeutics and vaccines.

“We have a total of 89 vaccines that are in development globally, including seven in clinical evaluation and some therapeutics are in clinical trials. WHO is committed to ensuring that as medicines and vaccines are developed, they are shared equitably with all countries and people.

“We do have the solidarity trial which is an international clinical trial to help find an effective treatment for Covid-19, launched by the WHO and partners. More than 100 countries have joined the solidarity trial and to date, over 1,200 patients have been randomized from the first five countries to evaluate the safety and efficacy full drug and drug combinations,” Braka said.